Search Results - "Fang, Wenfeng"

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer by Fang, Wenfeng, Huang, Yihua, Hong, Shaodong, Zhang, Zhonghan, Wang, Minghui, Gan, Jiadi, Wang, Wenjing, Guo, Honglin, Wang, Kai, Zhang, Li

“…Epidermal growth factor receptor exon 20 insertion (EGFRex20ins) mutations represent approximately 4-12% of EGFR mutations and are generally refractory to the…”
Get full text

Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer by Sheng, Jin, Fang, Wenfeng, Yu, Juan, Chen, Nan, Zhan, Jianhua, Ma, Yuxiang, Yang, Yunpeng, Huang, Yan, Zhao, Hongyun, Zhang, Li

“…The effects of treatments to programmed death ligand-1 (PD-L1) expression is unknown. The aim of this study was to investigate the impact of neoadjuvant…”
Get full text

KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma by Chen, Nan, Fang, Wenfeng, Lin, Zhong, Peng, Peijian, Wang, Juan, Zhan, Jianhua, Hong, Shaodong, Huang, Jiaxing, Liu, Lin, Sheng, Jin, Zhou, Ting, Chen, Ying, Zhang, Hongyu, Zhang, Li

“…It was reported that PD-L1 expression was correlated with genetic alterations. Whether PD-L1 was regulated by mutant Kirsten rat sarcoma viral oncogene homolog…”
Get full text

Research progress in immune checkpoint inhibitors for lung cancer in China by Gan, Jiadi, Huang, Yihua, Fang, Wenfeng, Zhang, Li

“…Immune checkpoint inhibitors (ICIs) have come to play an increasingly prominent role in the treatment of lung cancer, and some are recommended as a first-line…”
Get full text

Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes by Zhang, Li, MacIsaac, Kenzie D, Zhou, Ting, Huang, Pei-Yu, Xin, Chunlin, Dobson, Jason R, Yu, Kun, Chiang, Derek Y, Fan, Yue, Pelletier, Marc, Wang, Yan, Jaeger, Savina, Krishnamurthy Radhakrishnan, Viveksagar, JeBailey, Lellean, Skewes-Cox, Peter, Zhang, Jing, Fang, Wenfeng, Huang, Yan, Zhao, Hongyun, Zhao, Yuanyuan, Li, En, Peng, Bin, Huang, Alan, Dranoff, Glenn, Hammerman, Peter S, Engelman, Jeffrey, Bitter, Hans, Zeng, Yi-Xin, Yao, Yao

“…Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV) associated cancer characterized by a poor prognosis and a high level of lymphocyte infiltrate…”
Get full text

Acquired BRAF V600E Mutation Mediated Resistance to Osimertinib and Responded to Osimertinib, Dabrafenib, and Trametinib Combination Therapy by Huang, Yihua, Gan, Jiadi, Guo, Kunbin, Deng, Yangyang, Fang, Wenfeng

Get more information

Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer by Zhou, Huaqiang, Hu, Yi, Luo, Rongzhen, Zhao, Yuanyuan, Pan, Hui, Ji, Liyan, Zhou, Ting, Zhang, Lanjun, Long, Hao, Fu, Jianhua, Wen, Zhesheng, Wang, Siyu, Wang, Xin, Lin, Peng, Yang, Haoxian, Wang, Junye, Song, Mengmeng, Yi, Xin, Yang, Ling, Xia, Xuefang, Guan, Yanfang, Fang, Wenfeng, Yang, Yunpeng, Hong, Shaodong, Huang, Yan, Li, Pansong, Zhang, Yaxiong, Zhou, Ningning

“…Small cell lung cancer (SCLC) is a highly malignant tumor which is eventually refractory to any treatment. Intratumoral heterogeneity (ITH) may contribute to…”
Get full text

Therapy of lung cancer in China: introducing the special collection by Gan, Jiadi, Fang, Wenfeng, Zhang, Li

Get full text

Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis by Zhang, Yaxiong, Sheng, Jin, Kang, Shiyang, Fang, Wenfeng, Yan, Yue, Hu, Zhihuang, Hong, Shaodong, Wu, Xuan, Qin, Tao, Liang, Wenhua, Zhang, Li

“…It has been extensively proved that the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is superior to that of cytotoxic…”
Get full text

Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer by Fang, Wenfeng, Jin, Haoxuan, Zhou, Huaqiang, Hong, Shaodong, Ma, Yuxiang, Zhang, Yaxiong, Su, Xiaofan, Chen, Longyun, Yang, Yunpeng, Xu, Shengqiang, Liao, Yuwei, He, Yuming, Zhao, Hongyun, Huang, Yan, Gao, Zhibo, Zhang, Li

“…The role of ITH in melanoma, esophageal and gastric cancer, head and neck cancer, and kidney cancer is acceptable, which will further expand the cancer types…”
Get full text

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition by Zhang, Xuanye, Zhou, Yixin, Chen, Chen, Fang, Wenfeng, Cai, Xiuyu, Zhang, Xiaoshi, Zhao, Ming, Zhang, Bei, Jiang, Wenqi, Lin, Zuan, Ma, Yuxiang, Yang, Yunpeng, Huang, Yan, Zhao, Hongyun, Xu, Ruihua, Hong, Shaodong, Zhang, Li

“…BackgroundHepatitis B virus (HBV) reactivation is a serious complication in patients with cancers and HBV infection undergoing immunosuppressant treatment or…”
Get full text

Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas by Georgiou, Konstantinos, Chen, Longyun, Berglund, Mattias, Ren, Weicheng, de Miranda, Noel F.C.C., Lisboa, Susana, Fangazio, Marco, Zhu, Shida, Hou, Yong, Wu, Kui, Fang, Wenfeng, Wang, Xianhuo, Meng, Bin, Zhang, Li, Zeng, Yixin, Bhagat, Govind, Nordenskjöld, Magnus, Sundström, Christer, Enblad, Gunilla, Dalla-Favera, Riccardo, Zhang, Huilai, Teixeira, Manuel R., Pasqualucci, Laura, Peng, Roujun, Pan-Hammarström, Qiang

“…Diffuse large B-cell lymphoma (DLBCL) is one of the most common and aggressive types of B-cell lymphoma. Deregulation of proto-oncogene expression after a…”
Get full text

The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma by Hong, Shaodong, Liu, Dongbing, Luo, Shuzhen, Fang, Wenfeng, Zhan, Jianhua, Fu, Sha, Zhang, Yaxiong, Wu, Xuan, Zhou, Huaqiang, Chen, Xi, Chen, Gang, Zhang, Zhonghan, Zheng, Qiufan, Li, Xiaobo, Chen, Jinghao, Liu, Xingmin, Lei, Mengyue, Ye, Chen, Wang, Jian, Yang, Huanming, Xu, Xun, Zhu, Shida, Yang, Yunpeng, Zhao, Yuanyuan, Zhou, Ningning, Zhao, Hongyun, Huang, Yan, Zhang, Lanjun, Wu, Kui, Zhang, Li

“…Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare and distinct subtype of primary lung cancer characterized by Epstein-Barr virus (EBV) infection…”
Get full text

First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance by Ma, Yuxiang, Zheng, Xin, Zhao, Hongyun, Fang, Wenfeng, Zhang, Yang, Ge, Jieying, Wang, Lu, Wang, Weicong, Jiang, Ji, Chuai, Shaokun, Zhang, Zhou, Xu, Wanhong, Xu, Xiao, Hu, Pei, Zhang, Li

“…AC0010 is a mutation-selective, third-generation EGFR tyrosine kinase inhibitor (TKI). This aim of this first-in-human phase I trial was to determine the…”
Get more information

Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC) by Zhou, Ting, Zhan, Jianhua, Fang, Wenfeng, Zhao, Yuanyuan, Yang, Yunpeng, Hou, Xue, Zhang, Zhonghan, He, Xiaobo, Zhang, Yaxiong, Huang, Yan, Zhang, Li

“…Patients with small-cell lung cancer (SCLC) patients demonstrate varied survival outcomes. Previous studies have reported that lipoproteins are associated with…”
Get full text

Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations by Liang, Wenhua, Wu, Xuan, Fang, Wenfeng, Zhao, Yuanyuan, Yang, Yunpeng, Hu, Zhihuang, Xue, Cong, Zhang, Jing, Zhang, Jianwei, Ma, Yuxiang, Zhou, Ting, Yan, Yue, Hou, Xue, Qin, Tao, Dinglin, Xiaoxiao, Tian, Ying, Huang, Peiyu, Huang, Yan, Zhao, Hongyun, Zhang, Li

“…Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib, gefitinib, afatinib and icotinib are currently available as treatment for patients…”
Get full text

PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer by Zhou, Huaqiang, Liu, Jiaqing, Zhang, Yaxiong, Huang, Yan, Shen, Jiayi, Yang, Yunpeng, Fang, Wenfeng, Zhang, Li

“…Polybromo-1 ( PBRM1 ) gene is a promising biomarker for immunotherapy in clear cell renal cell carcinoma. But to our knowledge, the frequency and clinical…”
Get full text

Challenges in anticancer drug R&D in China by Zhao, Shen, Lv, Cheng, Gong, Jifang, Wenfeng, Fang, Hu, Xichun, Ba, Yi, Xiaoyuan, Chen, Zhimin, Yang, Shen, Lin, Zhang, Li

“…[...]29 (16%) phase 1 studies targeted the PD-1/PD-L1 pathway. [...]far, there are 12 PD-1 inhibitors and eight PD-L1 inhibitors being developed by 15 Chinese…”
Get full text

Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer by Zhao, Shen, Zhang, Zhonghan, Zhan, Jianhua, Zhao, Xin, Chen, Xinru, Xiao, Liyun, Wu, Kui, Ma, Yuxiang, Li, Mengzhen, Yang, Yunpeng, Fang, Wenfeng, Zhao, Hongyun, Zhang, Li

“…Abstract Background With the identification of new targetable drivers and the recent emergence of novel targeted drugs, using comprehensive genomic profiling…”
Get full text

Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients by Xin, Shuang, Fang, Wenfeng, Li, Jianwen, Li, Delan, Wang, Changzheng, Huang, Quanfei, Huang, Min, Zhuang, Wei, Wang, Xueding, Chen, Likun

“…Purpose Crizotinib is the first-line small molecule tyrosine kinase inhibitor for ALK -positive non-small cell lung cancer. In this study, a retrospective…”
Get full text